Hostname: page-component-6766d58669-zlvph Total loading time: 0 Render date: 2026-05-20T07:53:34.388Z Has data issue: false hasContentIssue false

The burden of isolation to the individual: a comparison between isolation for COVID-19 and for other influenza-like illnesses in Japan

Published online by Cambridge University Press:  10 December 2021

Shinya Tsuzuki*
Affiliation:
AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
Norio Ohmagari
Affiliation:
AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
Philippe Beutels
Affiliation:
Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
*
Author for correspondence: Shinya Tsuzuki, E-mail: stsuzuki@hosp.ncgm.go.jp
Rights & Permissions [Opens in a new window]

Abstract

At present, there is scarce evidence about the burden associated with the isolation of COVID-19 patients. We aimed to assess the differences between COVID-19 and other influenza-like illnesses (ILIs) in disease burden brought by isolation. We conducted an online survey of 302 respondents who had COVID-19 or other ILIs and compared the burden of isolation due to sickness with one-to-one propensity score matching. The primary outcomes are the duration and productivity losses associated with isolation, the secondary outcome is the health-related quality of life (HRQoL) valuation on the day of the survey. Acute symptoms of outpatient COVID-19 and other ILIs lasted 17 (interquartile range (IQR) 9–32) and 7 (IQR 4–10) days, respectively. The length of isolation due to COVID-19 was 18 (IQR 10–33) days and that due to other ILIs was 7 (IQR 4–11) days, respectively. The monetary productivity loss of isolation due to COVID-19 was 1424.3 (IQR 825.6–2545.5) USD and that due to other ILIs was 606.1 (IQR 297.0–1090.9) USD, respectively. HRQoL at the time of the survey was lower in the COVID-19 group than in the ‘other ILIs’ group (0.89 and 0.96, P = 0.001). COVID-19 infection imposes a substantial disease burden, even in patients with non-severe disease. This burden is larger for COVID-19 than other ILIs, mainly because the required isolation period is longer.

Information

Type
Original Paper
Creative Commons
Creative Common License - CCCreative Common License - BYCreative Common License - NCCreative Common License - ND
This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided that no alterations are made and the original article is properly cited. The written permission of Cambridge University Press must be obtained prior to any commercial use and/or adaptation of the article.
Copyright
Copyright © The Author(s), 2021. Published by Cambridge University Press
Figure 0

Table 1. Demographic characteristics of the participants

Figure 1

Table 2. Demographic characteristics of data after propensity score matching

Figure 2

Table 3. Comparison of outcomes between two groups

Figure 3

Table 4. Difference in each dimension of health-related quality of life between two groups by matched data

Figure 4

Fig. 1. Probability density curve of duration of symptoms and isolation, productivity loss and quality of life. Top left panel shows duration of symptoms. Top right panel shows duration of isolation. Bottom left panel shows productivity loss. Bottom right panel shows health-related quality of life. ILI, influenza-like illness; HRQoL, health-related quality of life. Blue area represents COVID-19 group and Red area represents other ILIs group.